Eczema (Atopic Dermatitis) Clinical Trials in Tampa
View 88 new treatments for Eczema (Atopic Dermatitis) in Tampa, FL, and nearby areas, such as Clearwater, Lakeland and St. Petersburg. Every day, Power helps hundreds of eczema patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Amlitelimab + Topical Corticosteroids for Atopic Dermatitis (AQUA)
Sanofi Clinic, Tampa + 2 more
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 [RIVER-AD]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 [RIVER-AD]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 [RIVER-AD] study).Show More
Verified
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Abrocitinib for Eczema
Research Clinic, Saint Petersburg + 1 more
This trial tests abrocitinib, a medication taken regularly, on people with atopic dermatitis who didn't respond well to another treatment or have facial redness. It works by reducing inflammation. Abrocitinib is approved in Europe, the United States, and other countries for the treatment of atopic dermatitis in adults whose disease is not controlled with other treatments.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Robert Bissonnette, MD
Principal Investigator
Ruxolitinib Cream for Atopic Dermatitis/Eczema
Incyte Clinic, Brandon + 1 more
This trial is testing a skin cream called ruxolitinib to see if it can help people with Atopic Dermatitis sleep better by reducing inflammation and itching. Ruxolitinib cream is used to treat inflammatory skin diseases like atopic dermatitis.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
Nemolizumab for Eczema
Galderma Clinic, Tampa + 6 more
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Lebrikizumab for Eczema
Eli Lilly Clinic, Tampa + 3 more
This trial will test the safety and effectiveness of lebrikizumab in people with severe eczema who have already tried another treatment called Dupilumab. Lebrikizumab aims to reduce skin inflammation by blocking a protein that causes it.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Upadacitinib + Topical Corticosteroids for Eczema
AbbVie Clinic, Clearwater + 1 more
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director
Rocatinlimab for Eczema
Amgen Clinic, Tampa + 2 more
This trial is testing a new medication called rocatinlimab to see if it works well and is safe when used alone. It targets patients who might benefit from a new treatment option.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
MD
Study Director
Tralokinumab for Atopic Hand Eczema
LEO Clinic, Tampa + 1 more
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to 4 weeks. For the first 16 weeks after screening, trial participants will receive either tralokinumab or dummy injections every two weeks. After the first 16 weeks, all trial participants will receive tralokinumab injections every two weeks for 16 weeks. The last part of the trial is a period of 4 weeks after the end of treatment period, where trial participants are off the drug for safety follow-up.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Medical Expert
Study Director
Amlitelimab for Atopic Dermatitis (COAST 2)
Sanofi Clinic, Tampa + 1 more
This trial tests amlitelimab injections for patients aged 12 and older with moderate to severe atopic dermatitis that isn't controlled by topical treatments. The injections aim to reduce inflammation and symptoms by targeting specific immune pathways.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
Abrocitinib for Atopic Dermatitis/Eczema
Pfizer Clinic, Saint Petersburg + 8 more
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Pfizer CT.gov Call Center
Study Director
Page 1 of 5
Frequently Asked Questions
Explore related conditions